Effects of losartan and captopril on QT dispersion in elderly patients with heart failure

Lancet

Volumn 354, Issue 9176, 1999, Pages 395-396

  Brooksby, P ^a   Robinson, P J ^d   Segal, R ^b   Klinger, G ^b   Pitt, B ^c   Cowley, A J C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; LOSARTAN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH;

EID: 0033620813     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)01354-9     Document Type: Article

References (5)

1. Pitt B., Segal R., Martinez F.A.et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 349:1997;747-752.
2. Thomas G.P., Ferrier G.R., Howlett S.E. Losartan exerts antiarrhythmic activity indepenent of angiotensin II receptor blockade in stimulated ventricular ischemia and reperfusion. J Pharm Exp Therapeut. 278:1996;1090-1097.
3. Barr C.S., Naas A., Freeman M., Lang C.C., Struthers A.D. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 343:1994;327-329.
4. Lynch J.J. Jr., Stump G.L., Wallace A.A.et al. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the ACE-inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. J Am Coll Cardiol. . (in press).
5. Rump L.C., Oberhauser V., Schwertfeger E., Schollmeyer P. Experimental evidence to support ELITE. Lancet. 351:1998;644-645.